Category: Cardiac Rhythm Management
Stealthy BioTrace Medical brings in $3.4 million in a hoped-for $3.5 million round for the heart pacing technology it's developing.
BioTrace Medical is closing in on its $3.5 million goal, having raised $3.4 million in a funding round, according to a regulatory filing.
BioTrace, which is backed by early-stage medtech angel Xandex Investments, is developing a temporary cardiac pacing device to treat reversible symptomatic bradycardia.
Johnson & Johnson's Biosense Webster subsidiary is the 1st to the U.S. market with a force-sensing ablation catheter for atrial fibrillation, the ThermoCool SmartTouch device.
Johnson & Johnson's (NYSE:JNJ) Biosense Webster subsidiary said it won pre-market approval from the FDA for its ThermoCool SmartTouch force-sensing ablation catheter, making it the 1st such device to hit the U.S. market.
St. Jude Medical warns physicians of a potential problem with its older pacemaker models when performing electrocautery procedures.
St. Jude Medical (NYSE:STJ) sent a letter to physicians late last month warning of the potential for problems with its older pacemakers during surgical procedures using electrocautery.
Medtronic touts the 1st U.S. implantation in the investigational device exemption trial of its Micra leadless pacemaker.
Medtronic (NYSE:MDT) said the 1st patient in a clinical trial of its its Micra pacemaker was implanted with the vitamin-sized device, which does not use wires threaded through blood vessels to regulate heart rhythm.
Medtronic's Reveal XT continuous heart monitor detected atrial fibrillation more often than current standards of care, including electrocardiograms and short-term diagnostic tests.
Results from Medtronic's (NYSE:MDT) CRYSTAL AF clinical trial found that the company's tiny Reveal XT continuous monitor performed better at detecting heart problems in stroke patients than current standards of care, the company reported.
The Reveal LINQ insertable cardiac monitor is now available in the U.S. and European Union member countries after landing regulatory clearance from regulators in both regions.
Medtronic (NYSE:MDT) landed both CE Mark approval in Europe and FDA 510(k) clearance in the U.S. for its Reveal LINQ insertable cardiac monitor.